170 related articles for article (PubMed ID: 25425214)
1. Randomised, double-blind, placebo-controlled trial of oral budesonide for prophylaxis of acute intestinal graft-versus-host disease after allogeneic stem cell transplantation (PROGAST).
Schmelz R; Bornhäuser M; Schetelig J; Kiani A; Platzbecker U; Schwanebeck U; Grählert X; Uharek L; Aust D; Baretton G; Schwerdtfeger R; Hampe J; Greinwald R; Mueller R; Ehninger G; Miehlke S
BMC Gastroenterol; 2014 Nov; 14():197. PubMed ID: 25425214
[TBL] [Abstract][Full Text] [Related]
2. Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study.
Yeshurun M; Shpilberg O; Herscovici C; Shargian L; Dreyer J; Peck A; Israeli M; Levy-Assaraf M; Gruenewald T; Mechoulam R; Raanani P; Ram R
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1770-5. PubMed ID: 26033282
[TBL] [Abstract][Full Text] [Related]
3. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
Finke J; Bethge WA; Schmoor C; Ottinger HD; Stelljes M; Zander AR; Volin L; Ruutu T; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Kolb HJ; Bertz H; Egger M; Grishina O; Socié G;
Lancet Oncol; 2009 Sep; 10(9):855-64. PubMed ID: 19695955
[TBL] [Abstract][Full Text] [Related]
4. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD.
Bertz H; Afting M; Kreisel W; Duffner U; Greinwald R; Finke J
Bone Marrow Transplant; 1999 Dec; 24(11):1185-9. PubMed ID: 10642806
[TBL] [Abstract][Full Text] [Related]
6. Corticosteroids for preventing graft-versus-host disease after allogeneic myeloablative stem cell transplantation.
Quellmann S; Schwarzer G; Hübel K; Greb A; Engert A; Bohlius J
Cochrane Database Syst Rev; 2008 Jul; (3):CD004885. PubMed ID: 18646116
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes.
Uberti JP; Ayash L; Braun T; Reynolds C; Silver S; Ratanatharathorn V
Bone Marrow Transplant; 2004 Sep; 34(5):425-31. PubMed ID: 15273705
[TBL] [Abstract][Full Text] [Related]
8. Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.
Kröger N; Solano C; Wolschke C; Bandini G; Patriarca F; Pini M; Nagler A; Selleri C; Risitano A; Messina G; Bethge W; Pérez de Oteiza J; Duarte R; Carella AM; Cimminiello M; Guidi S; Finke J; Mordini N; Ferra C; Sierra J; Russo D; Petrini M; Milone G; Benedetti F; Heinzelmann M; Pastore D; Jurado M; Terruzzi E; Narni F; Völp A; Ayuk F; Ruutu T; Bonifazi F
N Engl J Med; 2016 Jan; 374(1):43-53. PubMed ID: 26735993
[TBL] [Abstract][Full Text] [Related]
9. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal toxicity from the preparative regimen is associated with an increased risk of graft-versus-host disease.
Goldberg J; Jacobsohn DA; Zahurak ML; Vogelsang GB
Biol Blood Marrow Transplant; 2005 Feb; 11(2):101-7. PubMed ID: 15682070
[TBL] [Abstract][Full Text] [Related]
11. A single centre experience with allogeneic stem cell transplantation for severe aplastic anaemia in childhood.
Ladenstein R; Peters C; Minkov M; Emminger-Schmidmeier W; Mann G; Höcker P; Hawliczek R; Rosenmayr A; Fink FM; Niederwieser D; Gadner H
Klin Padiatr; 1997; 209(4):201-8. PubMed ID: 9293451
[TBL] [Abstract][Full Text] [Related]
12. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease.
Chao NJ; Parker PM; Niland JC; Wong RM; Dagis A; Long GD; Nademanee AP; Negrin RS; Snyder DS; Hu WW; Gould KA; Tierney DK; Zwingenberger K; Forman SJ; Blume KG
Biol Blood Marrow Transplant; 1996 May; 2(2):86-92. PubMed ID: 9118303
[TBL] [Abstract][Full Text] [Related]
13. Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin.
Finke J; Schmoor C; Lang H; Potthoff K; Bertz H
J Clin Oncol; 2003 Feb; 21(3):506-13. PubMed ID: 12560442
[TBL] [Abstract][Full Text] [Related]
14. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
15. A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.
Fong T; Trinkaus K; Adkins D; Vij R; Devine SM; Tomasson M; Goodnough LT; Lopez S; Graubert T; Shenoy S; Dipersio JF; Khoury HJ
Biol Blood Marrow Transplant; 2007 Oct; 13(10):1201-6. PubMed ID: 17889357
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD.
Sugita J; Matsushita T; Kashiwazaki H; Kosugi M; Takahashi S; Wakasa K; Shiratori S; Ibata M; Shono Y; Shigematsu A; Obara M; Fujimoto K; Endo T; Nishio M; Kondo T; Hashino S; Tanaka J; Asaka M; Imamura M
Bone Marrow Transplant; 2012 Feb; 47(2):258-64. PubMed ID: 21423118
[TBL] [Abstract][Full Text] [Related]
17. Budesonide: a novel treatment for oral chronic graft versus host disease.
Elad S; Or R; Garfunkel AA; Shapira MY
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003 Mar; 95(3):308-11. PubMed ID: 12627101
[TBL] [Abstract][Full Text] [Related]
18. Budesonide/Formoterol for bronchiolitis obliterans after hematopoietic stem cell transplantation.
Bergeron A; Chevret S; Chagnon K; Godet C; Bergot E; Peffault de Latour R; Dominique S; de Revel T; Juvin K; Maillard N; Reman O; Contentin N; Robin M; Buzyn A; Socié G; Tazi A
Am J Respir Crit Care Med; 2015 Jun; 191(11):1242-9. PubMed ID: 25835160
[TBL] [Abstract][Full Text] [Related]
19. Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial.
Cordonnier C; Chevret S; Legrand M; Rafi H; Dhédin N; Lehmann B; Bassompierre F; Gluckman E;
Ann Intern Med; 2003 Jul; 139(1):8-18. PubMed ID: 12834313
[TBL] [Abstract][Full Text] [Related]
20. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
